MC1R and melanin-based molecular probes for theranostic of melanoma and beyond

Acta Pharmacol Sin. 2022 Dec;43(12):3034-3044. doi: 10.1038/s41401-022-00970-y. Epub 2022 Aug 25.

Abstract

Malignant melanoma is accounting for most of skin cancer-associated mortality. The incidence of melanoma increased every year worldwide especially in western countries. Treatment efficiency is highly related to the stage of melanoma. Therefore, accurate staging and restaging play a pivotal role in the management of melanoma patients. Though 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET) has been widely used in imaging of tumor metastases, novel radioactive probes for specific targeted imaging of both primary and metastasized melanoma are still desired. Melanocortin receptor 1 (MC1R) and melanin are two promising biomarkers specifically for melanoma, and numerous research groups including us have been actively developing a plethora of radioactive probes based on targeting of MC1R or melanin for over two decades. In this review, some of the MC1R-targeted tracers and melanin-associated molecular imaging probes developed in our research and others have been briefly summarized, and it provides a quick glance of melanoma-targeted probe design and may contribute to further developing novel molecular probes for cancer theranostics.

Keywords: MC1R; melanin; melanoma; molecular probes; radiotracers.

Publication types

  • Review

MeSH terms

  • Humans
  • Melanins
  • Melanoma* / diagnostic imaging
  • Melanoma* / therapy
  • Molecular Probes
  • Precision Medicine
  • Receptor, Melanocortin, Type 1*

Substances

  • Receptor, Melanocortin, Type 1
  • Melanins
  • Molecular Probes